All Brands Owned by Alcon Inc.

What does Alcon own?
Alcon owns a portfolio of eye care brands across two business segments. In Surgical, the company owns intraocular lens brands including Clareon, PanOptix, and AcrySof, surgical equipment brands, and consumable products. In Vision Care, Alcon owns contact lens brands including TOTAL30, PRECISION7, DAILIES, and Air Optix, and ocular health brands including Systane and Tryptyr. The company also owns Aerie Pharmaceuticals, which produces glaucoma treatments.

Is Alcon publicly traded?
Yes, Alcon Inc. trades on the New York Stock Exchange under ticker ALC and on the SIX Swiss Exchange under the same ticker. The company was spun off from Novartis in April 2019 and began trading as an independent company. Alcon is incorporated in Switzerland and headquartered in Geneva.

Who founded Alcon?
Alcon was founded in 1945 by Robert Conron and William Conron in Fort Worth, Texas. The company's name is derived from the first syllables of "Alex" and "Conron." The founders initially focused on manufacturing ophthalmic products, including sterile ophthalmic solutions and instruments for eye surgery. Alcon was later acquired by Nestle in 1977 and then by Novartis in 2010 before being spun off as an independent company in 2019.

Where is Alcon headquartered?
Alcon is headquartered in Geneva, Switzerland. The company was incorporated in Switzerland ahead of its 2019 spin-off from Novartis. Alcon maintains significant operations in Fort Worth, Texas, where it was originally founded, along with manufacturing facilities in Switzerland, the United States, Mexico, Japan, China, India, and Belgium.

How many brands does Alcon own?
Alcon owns multiple eye care brands across its Surgical and Vision Care segments. Key brands include TOTAL30, PRECISION7, DAILIES, Air Optix, Systane, Tryptyr, PanOptix, Clareon, and Aerie Pharmaceuticals products. The company's portfolio is focused exclusively on eye care, with products spanning contact lenses, ocular health treatments, intraocular lenses, and surgical equipment.

Who owns Alcon?
Alcon is a publicly traded corporation owned by its shareholders. Major institutional holders include Vanguard Group, BlackRock, and other large asset managers. Novartis distributed all of its Alcon shares to Novartis shareholders in the April 2019 spin-off, retaining no ownership stake. No single shareholder holds a controlling interest in the company.

What is Alcon's revenue?
In FY2025, Alcon reported net sales of $10.3 billion, up 5% as reported and 4% on a constant currency basis. Diluted earnings per share were $1.98, and core diluted EPS was $3.07. The company generated $2.3 billion in cash from operating activities and $1.7 billion in free cash flow. In Q1 2026, net sales were $2.69 billion, up 10% as reported.

Has Alcon made any recent acquisitions?
Yes, Alcon has been active in acquisitions. In 2025, the company acquired a majority interest in Aurion Biotech for approximately $522 million, completed the acquisition of LumiThera for $124 million, and acquired approximately 91.2% of Cylite Pty Ltd. In March 2025, Alcon agreed to acquire LENSAR for up to $430 million, but terminated the agreement in March 2026. In 2022, Alcon acquired Aerie Pharmaceuticals for approximately $770 million.